Literature DB >> 16078844

Androsterone 3alpha-ether-3beta-substituted and androsterone 3beta-substituted derivatives as inhibitors of type 3 17beta-hydroxysteroid dehydrogenase: chemical synthesis and structure-activity relationship.

Béatrice Tchédam Ngatcha1, Van Luu-The, Fernand Labrie, Donald Poirier.   

Abstract

Type 3 17beta-hydroxysteroid dehydrogenase (17beta-HSD) is involved in the biosynthesis of androgen testosterone. To produce potent inhibitors of this key steroidogenic enzyme, we prepared a series of androsterone (ADT) derivatives by adding a variety of substituents at position 3. The 3beta-substituted ADT derivatives proved to be good inhibitors (IC(50) = 57-147 nM) with better inhibitory activities obtained for compounds bearing a propyl, s-butyl, cyclohexylalkyl, or phenylalkyl group. With an IC(50) value of 57 nM, the 3beta-phenylmethyl-ADT was 6-fold more potent than ADT, the lead compound, and 13-fold more potent than 4-androstene-3,17-dione, the natural enzyme substrate used itself as inhibitor. The 3alpha-ether-3beta-substituted ADT derivatives had a lower inhibitory activity compared to the 3beta-substituted ADT analogues except for the 3beta-phenylethyl-3alpha-methl-O-ADT (IC(50) = 73 nM), which proved to be a more potent inhibitor than 3beta-phenylethyl-ADT (IC(50) = 99 nM). The results of our study identified potent type 3 17beta-HSD inhibitors for potential use in the treatment of androgen-sensitive diseases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16078844     DOI: 10.1021/jm058179h

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  6 in total

1.  Development of Selective Steroid Inhibitors for the Glucose-6-phosphate Dehydrogenase from Trypanosoma cruzi.

Authors:  Fabrício Fredo Naciuk; Jéssica do Nascimento Faria; Amanda Gonçalves Eufrásio; Artur Torres Cordeiro; Marjorie Bruder
Journal:  ACS Med Chem Lett       Date:  2020-04-27       Impact factor: 4.345

2.  Comparative proteomic study reveals 17β-HSD13 as a pathogenic protein in nonalcoholic fatty liver disease.

Authors:  Wen Su; Yang Wang; Xiao Jia; Wenhan Wu; Linghai Li; Xiaodong Tian; Sha Li; Chunjiong Wang; Huamin Xu; Jiaqi Cao; Qifei Han; Shimeng Xu; Yong Chen; Yanfeng Zhong; Xiaoyan Zhang; Pingsheng Liu; Jan-Åke Gustafsson; Youfei Guan
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-15       Impact factor: 11.205

3.  Estrogen receptor-alpha mediates an intraovarian negative feedback loop on thecal cell steroidogenesis via modulation of Cyp17a1 (cytochrome P450, steroid 17alpha-hydroxylase/17,20 lyase) expression.

Authors:  Fuminori Taniguchi; John F Couse; Karina F Rodriguez; Judith M A Emmen; Donald Poirier; Kenneth S Korach
Journal:  FASEB J       Date:  2006-12-08       Impact factor: 5.191

4.  Species used for drug testing reveal different inhibition susceptibility for 17beta-hydroxysteroid dehydrogenase type 1.

Authors:  Gabriele Möller; Bettina Husen; Dorota Kowalik; Leena Hirvelä; Dariusz Plewczynski; Leszek Rychlewski; Josef Messinger; Hubert Thole; Jerzy Adamski
Journal:  PLoS One       Date:  2010-06-08       Impact factor: 3.240

5.  Investigation of the In Vitro and In Vivo efficiency of RM-532-105, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, in LAPC-4 prostate cancer cell and tumor models.

Authors:  Lucie Carolle Kenmogne; Jenny Roy; René Maltais; Mélanie Rouleau; Bertrand Neveu; Frédéric Pouliot; Donald Poirier
Journal:  PLoS One       Date:  2017-02-09       Impact factor: 3.240

6.  Synthesis of 5α-androstane-17-spiro-δ-lactones with a 3-keto, 3-hydroxy, 3-spirocarbamate or 3-spiromorpholinone as inhibitors of 17β-hydroxysteroid dehydrogenases.

Authors:  Guy Bertrand Djigoué; Béatrice Tchédam Ngatcha; Jenny Roy; Donald Poirier
Journal:  Molecules       Date:  2013-01-11       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.